WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. will begin launching TREDAPTIVE™ (ER niacin/laropiprant) in international markets including Mexico, the UK and Germany by the third quarter this year. TREDAPTIVE is a lipid-modifying therapy for patients with mixed dyslipidemia and primary hypercholesterolemia.
